The CEO of Chill Brands Group PLC, an international CBD conglomerate in the UK, Callum Sommerton, has announced that the company has begun production of a disposable electronic cigarette product that will be launched in the first quarter of 2023, and will be free of nicotine.
Sommerton also discussed a new agreement signed in the United States to expand its influence in the Midwest region.
According to 2FIRSTS, back in August of this year, Chill Brands Group PLC announced its decision to cease future development and sales of its non-tobacco nicotine product line in the United States. This decision was made in response to additional regulatory restrictions on synthetic nicotine products by the US government.
In March of this year, the United States Congress passed a federal appropriations bill that amended the definition of tobacco products, granting the FDA the power to regulate synthetic nicotine, including the company Chill's new smokeless tobacco nicotine pouch product.
As a result, Chill products will be required to submit a pre-market tobacco product application to continue selling their products legally, a process that could cost upwards of $400,000 per flavor. The company deems this commercially unfeasible.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
